Integra LifeSciences Holdings
IARTIntegra LifeSciences Holdings is a global medical device company specializing in surgical instruments, neuro and spinal devices, and wound care products. Founded in 1989, it focuses on developing innovative solutions for healthcare providers to improve patient outcomes across neurosurgery, orthopedics, and general surgery.
Company News
Integra LifeSciences reported Q3 2025 revenues of $402.1 million, a 5.6% increase from the previous year. The company saw healthy demand across its portfolio, with strong profitability driven by disciplined cost management and operational efficiencies.
The chronic wound care market is expected to grow at a CAGR of 4.17% from 2024 to 2031, driven by the high prevalence of chronic diseases and advancements in wound care technologies. The market is segmented by product, application, end-user, and region, with North America leading due to its developed healthcare infrastructure.
Integra Lifesciences (IART) shares fell 15.5% after the company reported Q2 results that topped estimates but provided disappointing full-year guidance, citing operational challenges and investments in compliance improvements.
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Investors have started to sour on the vaccine and postelection bets and small-cap stocks are taking it on the chin. Our call of the day says consider these higher quality, cheap names.
